

COMPLETE GENOMICS INC
Form 4
November 16, 2010

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
OVP VENTURE PARTNERS VI LP

2. Issuer Name and Ticker or Trading Symbol
COMPLETE GENOMICS INC
[GNOM]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)
11/16/2010

____ Director
____ Officer (give title below)
 10% Owner
____ Other (specify below)

C/O OVP VENTURE PARTNERS, 1010 MARKET STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
____ Form filed by One Reporting Person
 Form filed by More than One Reporting Person

KIRKLAND, WA 98033

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock, par value \$0.001	11/16/2010		C	6,313 A (1) 6,313	I	See Footnote (6)	
Common Stock, par value \$0.001	11/16/2010		C	5,150 A (3) 11,463	I	See Footnote (6)	
Common Stock, par	11/16/2010		C	3,535 A (4) 14,998	I	See Footnote	

Edgar Filing: COMPLETE GENOMICS INC - Form 4

value \$0.001								(6)
Common Stock, par value \$0.001	11/16/2010	C	9,477	A	5	24,475	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	C	4,767	A	5	29,242	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	X	3,134	A	\$ 1.5	32,376	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	F	523	D	\$ 9	31,853	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	X	647	A	\$ 7.56	32,500	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	F	544	D	\$ 9	31,956	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	X	690	A	\$ 7.56	32,646	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	F	580	D	\$ 9	32,066	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	X	79	A	\$ 7.56	32,145	I	See Footnote (6)
Common Stock, par value \$0.001	11/16/2010	F	67	D	\$ 9	32,078	I	See Footnote (6)
Common Stock, par value	11/16/2010	X	7	A	\$ 7.56	32,085	I	See Footnote (6)

Edgar Filing: COMPLETE GENOMICS INC - Form 4

\$0.001

Common
Stock, par
value
\$0.001

11/16/2010

F 6 D \$ 9 32,079 I

See
Footnote
(6)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Warrant to Purchase Series D Preferred Stock ⁽⁵⁾	\$ 7.56	11/16/2010		X	31,717	⁽⁹⁾ 02/13/2014	Common Stock	31,717
Warrant to Purchase Series D Preferred Stock ⁽⁵⁾	\$ 7.56	11/16/2010		X	647	⁽⁹⁾ 02/13/2014	Common Stock	647
Warrant to Purchase Series D Preferred Stock ⁽⁵⁾	\$ 7.56	11/16/2010		X	33,832	⁽⁹⁾ 04/06/2014	Common Stock	33,832
Warrant to Purchase Series D	\$ 7.56	11/16/2010		X	690	⁽⁹⁾ 04/06/2014	Common Stock	690

Preferred Stock ⁽⁵⁾									
Warrant to Purchase Series D Preferred Stock ⁽⁵⁾	\$ 7.56	11/16/2010	X	11,258	<u>(9)</u>	06/12/2014	Common Stock	11,258	
Warrant to Purchase Series D Preferred Stock ⁽⁵⁾	\$ 7.56	11/16/2010	X	79	<u>(9)</u>	06/12/2014	Common Stock	79	
Warrant to Purchase Series D Preferred Stock ⁽⁵⁾	\$ 7.56	11/16/2010	X	1,088	<u>(9)</u>	08/05/2014	Common Stock	1,088	
Warrant to Purchase Series D Preferred Stock ⁽⁵⁾	\$ 7.56	11/16/2010	X	7	<u>(9)</u>	08/05/2014	Common Stock	7	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
OVP VENTURE PARTNERS VI LP C/O OVP VENTURE PARTNERS 1010 MARKET STREET KIRKLAND, WA 98033		X		
OVP VI ENTREPRENEURS FUND LP 1010 MARKET STREET KIRKLAND, WA 98033		X		

Signatures

/s/ Charles P. Waite, Jr., Managing Member, OVP Venture Partners VI, L.P. 11/16/2010

__Signature of Reporting Person

Date

/s/ Charles P. Waite, Jr., Managing Member, OVP VI Entrepreneurs Fund, L.P. 11/16/2010

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each share of Series A Preferred Stock was automatically converted into common stock immediately prior to the completion of the

(1) Issuer's initial public offering. Shares are reported on an "as converted" basis giving effect to the 4.615101 conversion ratio applicable to such shares.

Each share of Series C Preferred Stock was automatically converted into common stock immediately prior to the completion of the

(3) Issuer's initial public offering. Shares are reported on an "as converted" basis giving effect to the 8.241076 conversion ratio applicable to such shares.

(4) Each share of Series D and Series E Preferred Stock was automatically converted into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering.

(5) The Exercise Price of the Warrant to Purchase Series B Preferred Stock is \$69.00 per share of Series B Preferred Stock. The exercise price is reported on an "as converted" basis after giving effect to the 5.926613 conversion ratio.

The shares are owned by OVP VI Entrepreneurs Fund, L.P. ("OVP VI Entrepreneurs"). OVMC VI LLC serves as the general partner of

(6) OVP VI Entrepreneurs. Charles P. Waite, Jr. is a managing member of OVMC VI LLC and shares voting and investment power over the shares held by OVP VI Entrepreneurs. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his proportionate pecuniary interest therein.

(9) The warrant is immediately exercisable.

Remarks:

Form 2 of 2

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.